CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.

OTCQB:CYDY - Post by User

CytoDyn Inc > Ready for takeoff

<< Previous

Bullboard Posts

Next >>

Comment by tikotikoon Jun 25, 2020 7:10am

67 Views

Post# 31189198

RE:RE:RE:Ready for takeoff

I agree. All the anecdotal evidence show that this may be the best drug for COVID19. It also has applications in several other diseases such as cancer and HIV, and no side effects. Official trial results will be known in a few days along with uplisting and other relevant news. There are good blogs in Yahoo, FB and Investorhub. Look for Jiro's comments (one of the best).
This can be a multi bagger of many multiples (10, 50, 100....)

<< Previous

Bullboard Posts

Next >>

Revolutionizing medical imaging with nanocarbon-based contrast drugs